Document is current
Any future updates will be listed below
-
Authors
Bruno, Samantha
Ghelli Luserna di Rorà, Andrea
Napolitano, Roberta
Soverini, Simona
Martinelli, Giovanni
Simonetti, Giorgia
-
Funding
Funding for this research was provided by:
ERA-Per-Med (ERAPERMED2018-275)
Associazione Italiana Contro le Leucemie - Linfomi e Mieloma
Alma Idea Junior Research Grant
- License Information
-
More Information
Article History
Received: 14 January 2022
Accepted: 11 April 2022
First Online: 30 April 2022
Declarations
:
: Not applicable.
: Not applicable.
: G.M. has competing interests with Menarini/Stemline Therapeutics, Pfizer, Astellas, Abbvie, Astrazeneca. G.Ma. has competing interests with Ariad/Incyte, Pfizer, Celgene/BMS, Amgen, Roche, AbbVie, GlaxoSmithKline, Astellas, Daiichi Sankyo, Takeda, Gilead, Astellas, Janssen, Novartis, MSD.
